BioCorRx Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2025. The company generated net revenues of $178,238 for the three months ended June 30, 2025, a substantial increase from $4,045 in the same period last year. For the six months, revenues reached $313,137, compared to $7,665 in the prior year. This growth is attributed primarily to new distribution sales from Lucemyra, an FDA-approved medication for opioid withdrawal, following the company's acquisition of related assets in March 2025.
Despite the increase in revenue, BioCorRx reported a net loss of $1,377,276 for the second quarter of 2025, compared to a loss of $1,233,996 in the same quarter of 2024. The total operating expenses rose to $1,592,158, up from $1,373,397 year-over-year, driven by increased consulting and administrative costs. The company also recognized a loss on the settlement of debt amounting to $55,000 during the quarter, which contributed to the overall increase in losses.
Operationally, BioCorRx has made strides in expanding its product offerings and market presence. The company’s acquisition of assets related to Lucemyra included a commitment to pay an upfront purchase price of $400,000 and ongoing royalties based on sales. The acquisition is expected to enhance the company’s revenue streams and market share in the addiction treatment sector. Additionally, the company reported a grant receivable of $153,728 as of June 30, 2025, reflecting its ongoing research initiatives supported by the National Institutes of Health.
Looking ahead, BioCorRx faces challenges, including a working capital deficit of $14,031,643 and an accumulated deficit of $85,283,967 as of June 30, 2025. The company has indicated that it will need to secure additional funding to support its operations and development activities. Management has expressed uncertainty regarding its ability to continue as a going concern without raising sufficient capital. The company plans to pursue private placements of equity and debt securities to meet its financial needs, although there are no guarantees that these funds will be available on favorable terms.
About BioCorRx Inc.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.